MX2023003540A - Mejora del bienestar fisico y mental de los pacientes con hipoparatiroidismo. - Google Patents

Mejora del bienestar fisico y mental de los pacientes con hipoparatiroidismo.

Info

Publication number
MX2023003540A
MX2023003540A MX2023003540A MX2023003540A MX2023003540A MX 2023003540 A MX2023003540 A MX 2023003540A MX 2023003540 A MX2023003540 A MX 2023003540A MX 2023003540 A MX2023003540 A MX 2023003540A MX 2023003540 A MX2023003540 A MX 2023003540A
Authority
MX
Mexico
Prior art keywords
physical
hypoparathyroidism
mental well
release
patients
Prior art date
Application number
MX2023003540A
Other languages
English (en)
Inventor
Kennett Sprogøe
Original Assignee
Ascendis Pharma Bone Diseases As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ascendis Pharma Bone Diseases As filed Critical Ascendis Pharma Bone Diseases As
Publication of MX2023003540A publication Critical patent/MX2023003540A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

La presente invención se refiere a un compuesto de PTH de liberación sostenida para su uso en un método para mejorar y tratar el bienestar físico y mental de pacientes con hipoparatiroidismo, en donde el compuesto de PTH de liberación sostenida libera PTH con una vida media de liberación de al menos 12 horas. En otro aspecto, la presente invención se relaciona con un método para mejorar el bienestar físico y mental de un paciente que tenga hipoparatiroidismo, que comprende administrar al paciente un compuesto de PTH de liberación sostenida, en donde el compuesto de PTH de liberación sostenida libera PTH con una vida media de liberación de al menos 12 horas, mejorando así el bienestar físico y mental del paciente.
MX2023003540A 2020-09-28 2021-09-27 Mejora del bienestar fisico y mental de los pacientes con hipoparatiroidismo. MX2023003540A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20198657 2020-09-28
EP20216049 2020-12-21
PCT/EP2021/076503 WO2022064035A1 (en) 2020-09-28 2021-09-27 Improvement of physical and mental well-being of patients with hypoparathyroidism

Publications (1)

Publication Number Publication Date
MX2023003540A true MX2023003540A (es) 2023-04-21

Family

ID=77913132

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023003540A MX2023003540A (es) 2020-09-28 2021-09-27 Mejora del bienestar fisico y mental de los pacientes con hipoparatiroidismo.

Country Status (9)

Country Link
US (1) US20230364199A1 (es)
EP (1) EP4217004A1 (es)
JP (1) JP2023543265A (es)
KR (1) KR20230079255A (es)
AU (1) AU2021349316A1 (es)
CA (1) CA3192772A1 (es)
IL (1) IL301411A (es)
MX (1) MX2023003540A (es)
WO (1) WO2022064035A1 (es)

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6624142B2 (en) 1997-12-30 2003-09-23 Enzon, Inc. Trimethyl lock based tetrapartate prodrugs
US7332164B2 (en) 2003-03-21 2008-02-19 Enzon Pharmaceuticals, Inc. Heterobifunctional polymeric bioconjugates
WO2004089280A2 (en) 2003-04-08 2004-10-21 Yeda Research And Development Co. Ltd. Reversible pegylated drugs
US7690003B2 (en) 2003-08-29 2010-03-30 Fuller Jeffrey C System and method for increasing data throughput using thread scheduling
TW200526254A (en) 2003-09-19 2005-08-16 Novo Nordisk As Novel GLP-1 derivatives
US8377917B2 (en) 2004-03-23 2013-02-19 Complex Biosystems Gmbh Polymeric prodrug with a self-immolative linker
US7968085B2 (en) 2004-07-05 2011-06-28 Ascendis Pharma A/S Hydrogel formulations
GB2427360A (en) 2005-06-22 2006-12-27 Complex Biosystems Gmbh Aliphatic prodrug linker
US8450269B2 (en) 2006-02-03 2013-05-28 Prolor Biotech Ltd. Long-acting growth hormone and methods of producing same
JP2010503707A (ja) 2006-09-15 2010-02-04 エンゾン ファーマスーティカルズ インコーポレイテッド オリゴヌクレオチドの送達を目的としたヒンダードエステル系生体分解性リンカー
EA021222B8 (ru) 2007-06-21 2015-11-30 ИксЭль-ПРОТЕИН ГМБХ Биологически активные белки, имеющие повышенную стабильность in vivo и/или in vitro
CA2693616A1 (en) 2007-07-11 2009-01-15 Enzon Pharmaceuticals, Inc. Polymeric drug delivery system containing a multi-substituted aromatic moiety
MX2010008024A (es) 2008-02-01 2010-12-21 Ascendis Pharma As Profarmaco que comprende un enlazador que se puede separar por si mismo.
WO2009143412A2 (en) 2008-05-23 2009-11-26 Enzon Pharmaceuticals, Inc. Polymeric systems containing intracellular releasable disulfide linker for the delivery of oligonucleotides
DK2393828T3 (en) 2009-02-03 2017-01-23 Amunix Operating Inc Extended recombinant polypeptides and compositions comprising same
WO2011012715A1 (en) 2009-07-31 2011-02-03 Ascendis Pharma As Biodegradable polyethylene glycol based water-insoluble hydrogels
EP2459227B1 (en) 2009-07-31 2021-03-17 Ascendis Pharma A/S Prodrugs containing an aromatic amine connected by an amide bond to a carrier
WO2011082368A2 (en) 2009-12-31 2011-07-07 Enzon Pharmaceuticals, Inc Polymeric conjugates of aromatic amine containing compounds including releasable urea linker
US20130030359A1 (en) 2010-01-22 2013-01-31 Ascendis Pharma A/S Dipeptide-based prodrug linkers for aromatic amine-containing drugs
US9561285B2 (en) 2010-01-22 2017-02-07 Ascendis Pharma As Carrier-linked carbamate prodrug linkers
US9062094B2 (en) 2010-01-22 2015-06-23 Ascendis Pharma As Dipeptide-based prodrug linkers for aliphatic amine-containing drugs
WO2011123813A2 (en) 2010-04-02 2011-10-06 Amunix Operating Inc. Binding fusion proteins, binding fusion protein-drug conjugates, xten-drug conjugates and methods of making and using same
EP2566335B1 (en) 2010-05-05 2016-06-29 Prolynx Llc Controlled release of active compounds from macromolecular conjugates
US8946405B2 (en) 2010-05-05 2015-02-03 Prolynx Llc Controlled release from solid supports
RU2604809C2 (ru) * 2010-05-13 2016-12-10 Дзе Дженерал Хоспитал Корпорейшн Аналоги паратиреоидного гормона и их применение
EP2571510B1 (en) 2010-05-21 2018-08-08 XL-protein GmbH Biosynthetic proline/alanine random coil polypeptides and their uses
WO2012002047A1 (ja) 2010-06-30 2012-01-05 Ｎｅｃソフト株式会社 属性判定方法、属性判定装置、プログラム、記録媒体および属性判定システム
CA2843503C (en) 2011-08-12 2020-12-22 Ulrich Hersel Polymeric hyperbranched carrier-linked prodrugs
CN103857413A (zh) 2011-08-12 2014-06-11 阿森迪斯药物股份有限公司 载体连接的曲罗尼尔前药
EP3643306A3 (en) 2011-08-12 2020-08-26 Ascendis Pharma A/S Carrier-linked prodrugs having reversible carboxylic ester linkages
AU2012296951B2 (en) 2011-08-12 2016-09-15 Ascendis Pharma A/S Protein carrier-linked prodrugs
CN103945870B (zh) 2011-09-07 2016-10-12 普罗林科斯有限责任公司 生物可降解交联的水凝胶
WO2013036857A1 (en) 2011-09-07 2013-03-14 Prolynx Llc Sulfone linkers
US20150087688A1 (en) 2012-04-25 2015-03-26 Ascendis Pharma A/S Prodrugs of hydroxyl-comprising drugs
EP2906617B1 (en) 2012-10-11 2018-03-14 Ascendis Pharma A/S Hydrogel prodrugs
EP2908845A1 (en) 2012-10-17 2015-08-26 Novo Nordisk Health Care AG Fatty acid acylated amino acids for growth hormone delivery
US20200354428A9 (en) * 2013-06-23 2020-11-12 Wisconsin Alumni Research Foundation Analogues of parathyroid hormone (1-34) that function as agonists of the parathyroid hormone receptor-1 and display modified activity profiles
AU2015299055C1 (en) 2014-08-06 2021-05-06 Ascendis Pharma A/S Prodrugs comprising an aminoalkyl glycine linker
MX2019003182A (es) 2016-09-29 2019-08-05 Ascendis Pharma Bone Diseases As Compuestos de hormona paratiroidea con bajas relaciones pico - valle.
MA46428A (fr) * 2016-09-29 2019-08-07 Ascendis Pharma Bone Diseases As Schéma posologique incrémentiel dans des composés de pth à libération contrôlée
EP3793587A1 (en) * 2018-05-18 2021-03-24 Ascendis Pharma Bone Diseases A/S Starting dose of pth conjugates
SG11202110436UA (en) 2019-04-05 2021-10-28 Prolynx Llc Improved conjugation linkers

Also Published As

Publication number Publication date
AU2021349316A1 (en) 2023-04-27
CA3192772A1 (en) 2022-03-31
IL301411A (en) 2023-05-01
KR20230079255A (ko) 2023-06-05
WO2022064035A1 (en) 2022-03-31
US20230364199A1 (en) 2023-11-16
EP4217004A1 (en) 2023-08-02
JP2023543265A (ja) 2023-10-13

Similar Documents

Publication Publication Date Title
EP4233861A3 (en) Compositions for treatment of essential tremor
GB0410266D0 (en) Treatment of apoptosis
CY1111478T1 (el) Ενδειξη δοσολογιας προγεστερονης στην αντιμετωπιση τραυματικης εγκεφαλικης βλαβης
MX2022011804A (es) Uso de agentes para el tratamiento de condiciones respiratorias.
MX2021008247A (es) Combinacion de dextrometorfano y bupropion para el tratamiento de depresion.
MX2023005455A (es) Metodos de tratamiento de la insuficiencia cardiaca mediante la administracion de omecamtiv mecarbil.
NI201100147A (es) Métodos para tratar infartos agudos de miocardio y trastornos relacionados.
HK1086186A1 (en) Use of spongosine (2-methoxyadenosein) for preparing pharmaceutical for the treatment of pain
RU2008127882A (ru) Лечение пищевода барретта
RS20050344A (en) Treatment for hemorrhagic shock
MX2008001520A (es) Composiciones de tizanidina y metodos de tratamiento usando las composiciones.
MX2021015352A (es) Métodos para tratar la enfermedad de fabry en pacientes que tienen insuficiencia renal.
MXPA05010597A (es) Prevencion y tratamiento de cancer de mama con tamoxifen 4-hidroxi.
MX2022000143A (es) Metodos novedosos.
NZ767378A (en) Dosage forms and methods for enantiomerically enriched or pure bupropion
MX2023003540A (es) Mejora del bienestar fisico y mental de los pacientes con hipoparatiroidismo.
WO2011031890A4 (en) Cancer stem cell-targeted and drug resistant cancer therapy
Engelsman et al. Controlled clinical trial of L-dopa and nafoxidine in advanced breast cancer: an EORTC study.
MX2021008986A (es) Metodos de tratamiento de un paciente con enfermedad de parkinson.
MX2020007817A (es) Prevención y tratamiento del trastorno del sueño.
GB0405381D0 (en) A method and means for treating heart failure
WO2008088987B1 (en) Treatment of pain with naloxone
CA2516458A1 (en) Use of kahalalide compounds for the manufacture of a medicament for the treatment of psoriasis
MX2022011171A (es) Compuestos con actividad inmunomodulatoria y usos terapeuticos de estos.
MX2023002350A (es) Composiciones y metodos para mejorar enfermedades y trastornos neurologicos.